To include your compound in the COVID-19 Resource Center, submit it here.

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE